U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07591168) titled 'A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes' on May 09.
Brief Summary: This study is an open-label, multicenter, non-randomized Phase Ib/II clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BL-M11D1 for injection in patients with relapsed/refractory myelodysplastic syndromes.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Myelodysplastic Syndromes
Intervention:
DRUG: BL-M11D1
Administration by intravenous infusion for a cycle of 4 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Pu...